The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 16, 2014, Pages 2393-2399

  Szalek E ^a   Karbownik, A ^a   Sobanska, K ^a   Polom W ^b   Grabowski, T ^c   Wolc, A ^d   Matuszewski, M ^b   Grzeskowiak, E ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b University Clinical Centre   (Poland)

^c POLPHARMA BIOLOGICS   (Poland)

^d IOWA STATE UNIVERSITY   (United States)

Author keywords

Chronopharmacokinetics; Glycaemia; Rabbits; SU12662; Sunitinib

Indexed keywords

GLUCOSE; N DEETHYLSUNITINIB; SUNITINIB; ANTINEOPLASTIC AGENT; GLUCOSE BLOOD LEVEL; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL RABBIT; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INVESTIGATIVE PROCEDURES; MALE; NONHUMAN; SINGLE DRUG DOSE; VALIDATION STUDY; ANALYSIS; ANIMAL; BLOOD; DRUG ADMINISTRATION; RABBIT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLOOD GLUCOSE; DRUG ADMINISTRATION SCHEDULE; INDOLES; MALE; PROTEIN KINASE INHIBITORS; PYRROLES; RABBITS;

EID: 84927173112     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. LEVI F. From circadian rhythms to cancer chronotherapeutics. Chronobiol Int 2002; 19: 1-19.
2. SAVVIDIS C, KOUTSILIERIS M. Circadian rhythm disruption in cancer biology. Mol Med 2012; 18: 1249- 1260.
3. MORMONT MC, LEVI F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97: 155-169.
4. BURNS RE, SCHEVING LE, TSAI TH. Circadian rhythms in DNA synthesis and mitosis in normal mice and in mice bearing the Lewis lung carcinoma. Eur J Cancer 1979; 15: 233-244.
5. FAIVRE L, GOMO C, MIR O, TAIEB F, SCHOEMANNTHOMAS A, ROPERT S, VIDAL M, DUSSER D, DAUPHIN A, GOLDWASSER F, BLANCHET B. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2345-2350.
6. PAPAETIS GS, SYRIGOS KN. Sunitinib: A multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapy. BioDrugs 2009; 23: 377-389.
7. HAZNEDAR JO, PATYNA S, BELLO CL, PENG GW, SPEED W, YU X, ZHANG Q, SUKBUNTHERNG J, SWEENY DJ, ANTONIAN L, WU EY. Single- And multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009; 64: 691-706.
8. HOUK BE, BELLO CL, KANG D, AMANTEA M. A population pharmacokinetic metaanalysis of sunitinib malate (SU 11248) and its primary metabolite (SU 12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-2506.
9. FAIVRE S, DELBALDO C, VERA K, ROBERT C, LOZAHIC S, LASSAU N, BELLO C, DEPRIMO S, BREGA N, MASSIMINI G, ARMAND JP, SCIGALLA P, RAYMOND E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
10. KIM A, BALIS FM, WIDEMANN BC. Sorafenib and sunitinib. Oncologist 2009; 14: 800-805.
11. BRITTEN CD, KABBINAVAR F, HECHT JR, BELLO CL, LI J, BAUM C, SLAMON D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61: 515-524.
12. CALDELAS I, TEJADILL A, GONZALES B, MUNTUFAR R, HUDSON R. Diurnal pattern of clock gene expression in the hypothalamus of the newborn rabbits. Neuroscience 2007; 144: 395- 401.
13. CHALLET E, CALDELAS I, GRAFF C, PEVET P. Synchronization of the molecular clockwork by light- And food-related cues in mammals. Biol Chem 2003; 384: 711-719.
14. JILGE B, HUDSON R. Diversity and development of circadian rhythms in european rabbits. Chronobiol Int 2001; 18: 1-26.
15. MEISEL JA, FALLON EM, LE HD, NEHRA D, DE-MEIJER VE, RODIG SJ, PUDER M. Sunitinib inhibits postoperative adhesions in a rabbit model. Surgery 2011; 150: 32-38.
16. BEN-CHERIF W, DRIDI I, AOUAM K, BEN-ATTIA M, REINBERG A, BOUGHATTAS NA. Circadian variation of Valproic acid pharmacokinetics in mice. Eur J Pharm Sci 2013; 49: 468-473.
17. DRIDI D, BEN-ATTIA M, REINBERG A, BOUGHATTAS NA. Circadian rhythms in the toxic effects of the histamine antagonist cetirizine in mice. Pathol Biol 2005; 53: 193-198.
18. DRIDI D, BOUGHATTAS NA, AOUAM K, REINBERG A, BEN-ATTIA M. Circadian time-dependent differences in murine tolerance to the antihistaminic agent loratadine. Chronobiol Int 2005; 22: 499-514.
19. KHEDHAIER A, BEN-ATTIA M, GADACHA W, SANI M, BOUZOUITA K, CHOUCHANE L, MECHKOURI M, REINBERG A, BOUGHATTAS NA. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int 2003; 20: 1103-1116.
20. ETIENNE-GRIMALDI MC, CARDOT JM, FRANÇOIS E, RENÉE N, DOUILLARD JY, GAMELIN E, MILANO G. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Clin Pharmacol Ther 2011; 83: 413-415.
21. LÉVI F, BENAVIDES M, CHEVELLE C, LE-SAUNIER F, BAILLEUL F, MISSET JL, REGENSBERG C, VANNETZEL JM, REINBERG A, MATHÉ G. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: A randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 1990; 8: 705-714.
22. LÉVI F, FOCAN C, KARABOUÉ A, DE-LA-VALETTE V, FOCAN-HENRARD D, BARON B, KREUTZ F, GIACCHETTI S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 2007; 59: 1015-1035.
23. BHOJANI N, JELDRES C, PATARD JJ, PERROTTE P, SUARDI N, HUTTERER G, PATENAUDE F, OUDARD S, KARAKIEWICZ PI. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-930.
24. KOŠIR R, SPANINGER K, ROZMAN D. Circadian events in human diseases and in cytochrome P450-related drug metabolism and therapy. IUBMB Life 2013; 65: 487-496.
25. TAKIGUCHI T, TOMITA M, MATSUNAGA N, NAKAGAWA H, KOYANAGI S, OHDO S. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet Genomics 2007; 17: 1047- 1056.
26. AGOSTINO NM, CHINCHILLI VM, LYNCH CJ, KOSZYKSZEWCZYK A, GINGRICH R, SIVIK J, DRABICK JJ. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011; 17: 197-202.
27. BILLEMONT B, MEDIONI J, TAILLADE L, HELLEY D, MERIC JB, RIXE O, OUDARD S. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008; 99: 1380- 1382.
28. LEE Y, JUNG HS, CHOI HJ, KIM MJ, KIM TM, PARK KS, KIM SY. Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: A case report. Diabetes Res Clin Pract 2011; 93: 68-70.
29. OH JJ, HONG SK, JOO YM, LEE BK, MIN SH, LEE S, BYUN SS, LEE SE. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42: 314-317.